Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial

Abstract

BackgroundThe TeloVac study indicated GV1001 did not improve the survival of advanced pancreatic ductal adenocarcinoma (PDAC). However, the cytokine examinations suggested that high serum eotaxin levels may predict responses to GV1001. This Phase III trial assessed the efficacy of GV1001 with gemcitabine/capecitabine for eotaxin-high patients with untreated advanced PDAC.MethodsPatients recruited from 16 hospitals received gemcitabine (1000mg/m(2), D 1, 8, and 15)/capecitabine (830mg/m(2) BID for 21 days) per month either with (GV1001 group) or without (control group) GV1001 (0.56mg; D 1, 3, and 5, once on week 2-4, 6, then monthly thereafter) at random in a 1:1 ratio. The primary endpoint was overall survival (OS) and secondary end points included time to progression (TTP), objective response rate, and safety.ResultsTotal 148 patients were randomly assigned to the GV1001 (n=75) and control groups (n=73). The GV1001 group showed improved median OS (11.3 vs. 7.5 months, P=0.021) and TTP (7.3 vs. 4.5 months, P=0.021) compared to the control group. Grade >3 adverse events were reported in 77.3% and 73.1% in the GV1001 and control groups (P=0.562), respectively.ConclusionsGV1001 plus gemcitabine/capecitabine improved OS and TTP compared to gemcitabine/capecitabine alone in eotaxin-high patients with advanced PDAC.Clinical trial registrationNCT02854072.